Logo

Agendia Licenses Rosetta s Gene Expression-Analysis Software

Oct 03, 2005

NEW YORK, Oct. 3 (GenomeWeb News) - Agendia has licensed Rosetta's Resolver software and the two companies will collaborate to offer diagnostics tools for gene-expression analysis, the firms said today.

 

Rosetta and Agendia will "enable interoperability between the Resolver system and Agendia's clinical and gene expression database" to support Agendia's research and development of diagnostic products and services, Yelena Shevelenko, vice president and general manager of Rosetta, said in a statement.

 

Financial terms of the deal were not disclosed.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.